«SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials». Lancet393 (10166): 31–9. January 2019. doi:10.1016/S0140-6736(18)32590-X. PMID30424892. «However, in patients with atherosclerotic cardiovascular disease, the effect of empagliflozin on cardiovascular death was more pro-nounced than that of canagliflozin or dapagliflozin».
«Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction». New England Journal of Medicine381 (21): 1995–2008. November 2019. doi:10.1056/NEJMoa1911303. PMID31535829.
«SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials». Lancet393 (10166): 31–9. January 2019. doi:10.1016/S0140-6736(18)32590-X. PMID30424892. «However, in patients with atherosclerotic cardiovascular disease, the effect of empagliflozin on cardiovascular death was more pro-nounced than that of canagliflozin or dapagliflozin».
«Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction». New England Journal of Medicine381 (21): 1995–2008. November 2019. doi:10.1056/NEJMoa1911303. PMID31535829.